12.1: From Discovery to the Market

Quality and Regulatory Compliance in Bioscience · LibreTexts

0%

Contents

    Text

    Size
    100%
    Theme
    Typeface
    Line length
    Spacing

    Read aloud

    How

    Speed: 1×
    Light up
    Highlight

    Symbols: Mulberry Symbols, © 2018–2026 Steve Lee, CC BY-SA 4.0 (licence, the set), the site's own copies.

    From LibreTexts, under CC BY-SA 4.0, as the source states it; its equations are written in TeX, which the PDF shows typeset. This page at LibreTexts.

    12.1: From Discovery to the Market

    This work can take years. The time, cost, and chance of success depend on the product, the disease, and the development plan. A team may stop development when the risks are too high, the benefits are too small, or the product cannot be made reliably.

    The drug substance is the active material. It is often called the active pharmaceutical ingredient (API). The drug product is the finished form a patient receives, such as a tablet or an injectable solution. A therapeutic biological product can be a medicine such as a therapeutic protein or antibody. The term biopharmaceutical often refers to a medicine made using biological systems or biotechnology.

    Biotechnology development and ongoing oversight.png


    This page titled 12.1: From Discovery to the Market was last modified on Mon, 09 Nov 2026 04:52:41 GMT and is shared under a CC BY-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.